The quest for an Alzheimer therapy

Stefano F. Cappa

Research output: Contribution to journalShort survey

8 Citations (Scopus)

Abstract

This mini-review considers three different approaches to the therapy and prevention of Alzheimer's disease (AD): replacement therapy, disease modification, and multi-level interventions. Each of these research frameworks has direct implications at the clinical level, leading to an emphasis on different time points of the AD continuum. While all perspectives continue to play an important role in current efforts to reach the ambitious target of an effective therapy or prevention of AD by 2025, it is clear that novel paradigms are needed, including new models of clinical trial design. This goal can only be accomplished by a concerted effort of academia, governmental agencies, and industry.

Original languageEnglish
Article number108
JournalFrontiers in Neurology
Volume9
Issue numberMAR
DOIs
Publication statusPublished - Mar 1 2018

Fingerprint

Alzheimer Disease
Industry
Therapeutics
Clinical Trials
Research

Keywords

  • Alzheimer disease
  • Amyloid
  • Dementia prevention
  • Diagnostic criteria
  • Therapy

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

The quest for an Alzheimer therapy. / Cappa, Stefano F.

In: Frontiers in Neurology, Vol. 9, No. MAR, 108, 01.03.2018.

Research output: Contribution to journalShort survey

Cappa, Stefano F. / The quest for an Alzheimer therapy. In: Frontiers in Neurology. 2018 ; Vol. 9, No. MAR.
@article{9c07933a3ab04904b99f6b23912b4579,
title = "The quest for an Alzheimer therapy",
abstract = "This mini-review considers three different approaches to the therapy and prevention of Alzheimer's disease (AD): replacement therapy, disease modification, and multi-level interventions. Each of these research frameworks has direct implications at the clinical level, leading to an emphasis on different time points of the AD continuum. While all perspectives continue to play an important role in current efforts to reach the ambitious target of an effective therapy or prevention of AD by 2025, it is clear that novel paradigms are needed, including new models of clinical trial design. This goal can only be accomplished by a concerted effort of academia, governmental agencies, and industry.",
keywords = "Alzheimer disease, Amyloid, Dementia prevention, Diagnostic criteria, Therapy",
author = "Cappa, {Stefano F.}",
year = "2018",
month = "3",
day = "1",
doi = "10.3389/fneur.2018.00108",
language = "English",
volume = "9",
journal = "Frontiers in Neurology",
issn = "1664-2295",
publisher = "Frontiers Research Foundation",
number = "MAR",

}

TY - JOUR

T1 - The quest for an Alzheimer therapy

AU - Cappa, Stefano F.

PY - 2018/3/1

Y1 - 2018/3/1

N2 - This mini-review considers three different approaches to the therapy and prevention of Alzheimer's disease (AD): replacement therapy, disease modification, and multi-level interventions. Each of these research frameworks has direct implications at the clinical level, leading to an emphasis on different time points of the AD continuum. While all perspectives continue to play an important role in current efforts to reach the ambitious target of an effective therapy or prevention of AD by 2025, it is clear that novel paradigms are needed, including new models of clinical trial design. This goal can only be accomplished by a concerted effort of academia, governmental agencies, and industry.

AB - This mini-review considers three different approaches to the therapy and prevention of Alzheimer's disease (AD): replacement therapy, disease modification, and multi-level interventions. Each of these research frameworks has direct implications at the clinical level, leading to an emphasis on different time points of the AD continuum. While all perspectives continue to play an important role in current efforts to reach the ambitious target of an effective therapy or prevention of AD by 2025, it is clear that novel paradigms are needed, including new models of clinical trial design. This goal can only be accomplished by a concerted effort of academia, governmental agencies, and industry.

KW - Alzheimer disease

KW - Amyloid

KW - Dementia prevention

KW - Diagnostic criteria

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=85042771605&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042771605&partnerID=8YFLogxK

U2 - 10.3389/fneur.2018.00108

DO - 10.3389/fneur.2018.00108

M3 - Short survey

AN - SCOPUS:85042771605

VL - 9

JO - Frontiers in Neurology

JF - Frontiers in Neurology

SN - 1664-2295

IS - MAR

M1 - 108

ER -